Vehicle-treated mice demonstrated median >95% bone marrow replacement by human CD45 + AML cells, decreased to median ~60% by THU + decitabine 5 days every 4 weeks, and decreased to median <10% by THU + decitabine 2X/week, with inversely corresponding murine Cd45+ cells (Supplementary Fig. S6D). This evidence concerns the gene PTPRC and acute myeloid leukemia.